Macquarie Group
MRNS

Macquarie Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Macquarie Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,749
Closed -$3.22K – 1978
2024
Q2 		$3.22K Buy
+2,749
New +$6.88K ﹤0.01% 1759

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Macquarie Group's MRNS Position: Q3 2024 in Review

Macquarie Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 2,749 shares — an estimated $3.22K sold.

Macquarie Group first reported a position in MRNS in Q2 2024 and held it in 1 quarter. The position peaked at $3.22K in Q2 2024. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Macquarie Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 2,749 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $3.22K.
  • Macquarie Group first reported a position in Marinus Pharmaceuticals, Inc in Q2 2024 and held it in 1 quarter.
  • Macquarie Group's Marinus Pharmaceuticals, Inc position peaked at $3.22K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.